Rebecca Taub, Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 92,226 shares at $359.71 ($32.8M) on 2025-08-12, disclosed to the SEC on 2025-08-13.
Scheduled sale ($32.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $350.18 | 2,980 | $1.0M | 3.2% |
| 2 | $350.18 | 2,980 | $1.0M | 3.2% |
| 3 | $351.02 | 220 | $77K | 0.2% |
| 4 | $351.02 | 220 | $77K | 0.2% |
| 5 | $350.87 | 3,580 | $1.3M | 3.8% |
| 6 | $350.87 | 3,580 |
| $1.3M |
| 3.8% |
| 7 | $351.60 | 2,870 | $1.0M | 3.1% |
| 8 | $351.60 | 2,870 | $1.0M | 3.1% |
| 9 | $352.45 | 1,175 | $414K | 1.3% |
| 10 | $352.45 | 1,175 | $414K | 1.3% |
| 11 | $354.04 | 4,587 | $1.6M | 5.0% |
| 12 | $354.04 | 4,587 | $1.6M | 5.0% |
| 13 | $354.97 | 6,479 | $2.3M | 7.0% |
| 14 | $354.97 | 6,479 | $2.3M | 7.0% |
| 15 | $355.95 | 5,752 | $2.0M | 6.2% |
| 16 | $355.95 | 5,752 | $2.0M | 6.2% |
| 17 | $356.88 | 4,864 | $1.7M | 5.3% |
| 18 | $356.88 | 4,864 | $1.7M | 5.3% |
| 19 | $357.85 | 6,715 | $2.4M | 7.3% |
| 20 | $357.85 | 6,715 | $2.4M | 7.3% |
| 21 | $358.81 | 6,541 | $2.3M | 7.2% |
| 22 | $358.81 | 6,541 | $2.3M | 7.2% |
| 23 | $359.71 | 700 | $252K | 0.8% |
| Total | $355.28 avg | 92,226 | $32.8M | 100% |
| Filing → |
| MDGL | SELL | 2026-01-20 | $1.1M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $242K | — | Filing → |
| MDGL | SELL | 2026-01-13 | $18.9M | — | Filing → |